Bill Sibble

Bill Sibble, CEO of Madrigal Pharmaceuticals, dives into the company's impressive Q4 results, highlighting the impact of their promising MASH drug. He discusses how this recent success is contributing to Madrigal's stock surge. The conversation also touches on the competitive pharmaceutical landscape and the strategic moves required to navigate it effectively. Additionally, the podcast examines Nvidia's latest financial performance and its ripple effects on the broader market, alongside emerging trends in tech and pharmaceuticals.